Omeros shares jump 10.42% after-hours as Boral reiterates "buy" and Novo Nordisk deal fuels optimism.

Omeros surged 10.42% in after-hours trading following a combination of positive analyst activity and recent earnings performance. D. Boral Capital reiterated a "buy" rating with a $36.00 price target, reinforcing confidence in the stock despite a recent downgrade from Wall Street Zen. Additionally, Omeros reported quarterly earnings that beat estimates by $0.39, contributing to the upward momentum. The stock's strong performance also appears linked to ongoing interest in its zaltenibart licensing deal with Novo Nordisk, which was previously highlighted by H.C. Wainwright with an increased price target.